ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Natural History, Genetic Bases and Phenotype-Genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations

This study is currently recruiting participants.
Verified by Institut National de la Santé Et de la Recherche Médicale, France, October 2007

Sponsors and Collaborators: Institut National de la Santé Et de la Recherche Médicale, France
Assistance Publique - Hôpitaux de Paris
Information provided by: Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier: NCT00136630
  Purpose

The autosomal dominant spinocerebellar degenerations are a highly heterogeneous, clinically and genetically, group of rare diseases and of severe evolution. So far, the responsible genes for less than 50% of the cases are known and because of their rarity, there are no phenotype-genotype correlations and well-defined disease history.

The aims of the project are to develop and validate quantitative tools of the cerebellar syndrome and of the spasticity, to establish links between the phenotype and the result of the molecular analysis, to identify new loci/genes responsible for these disorders, and to establish the natural history of the disease according to the genotype.

To this end, a prospective and multicentric study is proposed for recruiting and evaluating, clinically, a cohort of 225 patients; 150 of them are already followed-up in the centers involved. A DNA collection will be set up in order to search for the implication of new loci and genes. A clinico-genetic database will be set up combining data from successive clinical evaluations and those of genotyping.

This strategy will allow access to genetic counselling and molecular diagnosis (positive, presymptomatic or prenatal diagnoses), based on a rational strategy from phenotype-genotype correlations and the information concerning the relative frequency of the genes. The detailed description, with the help of new evaluation tools and of the follow-up of the natural history of the disease according to the genotype, constitutes a crucial step in the design of therapeutical trials in these orphan disorders. Furthermore, the regular follow-up by specialized centers will allow better care of the patients.


Condition Phase
Spinocerebellar Ataxias
Spastic Paraplegias
Phase I

Genetics Home Reference related topics:   familial encephalopathy with neuroserpin inclusion bodies    Friedreich ataxia    spastic paraplegia type 4    Troyer syndrome   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Prospective
Official Title:   Natural History, Genetic Bases and Phenotype-Genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations

Further study details as provided by Institut National de la Santé Et de la Recherche Médicale, France:

Estimated Enrollment:   225
Study Start Date:   May 2005
Estimated Study Completion Date:   December 2007

  Eligibility
Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Progressive ataxia or paraplegia,
  • Familial history of the disease (patients),
  • Over 18 years of age (controls, 20 by range of age, from 20 to 70)
  • No presentation of neurological or osteoarticular disorders

Exclusion Criteria:

  • Refusal to participate in the protocol,
  • An unknown familial history,
  • Presenting with an interrecurrent disorder making the evaluation of the disease (stroke, dementia) impossible
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00136630

Contacts
Contact: Alexandra Dürr, MD, PhD     0033142162182     durr@ccr.jussieu.fr    

Locations
France
Hôpital Pitié-Salpêtrière     Recruiting
      Paris, France, 75013
      Contact: Alexandra Dürr, MD, PhD     0033142162182     durr@ccr.jussieu.fr    
      Principal Investigator: Alexandra Dürr, MD, PhD            
      Sub-Investigator: Bertrand Fontaine, MD, PhD            
      Sub-Investigator: Charles Dyuckaerts, MD, PhD            
Hôpital Neurologique Pierre Wertheimer     Recruiting
      Lyon, France, 69003
      Contact: Emmanuel Broussolle, MD, PhD     0033472357607     emmanuel.broussolle@chu-lyon.fr    
      Principal Investigator: Emmanuel Broussolle, MD, PhD            
Hôpital Carémeau     Recruiting
      Nîmes, France, 30000
      Contact: Pierre Labauge, MD, PhD     003466683263     labauge@hotmail.com    
      Principal Investigator: Pierre Labauge, MD, PhD            
Hôpital Pellegrin     Recruiting
      Bordeaux, France, 33000
      Contact: Cyril Goizet, MD     0033556795646     cyril.goizet@chu-bordeaux.fr    
      Principal Investigator: Cyril Goizet, MD            
CHU de Grenoble     Recruiting
      Grenoble, France, 38000
      Contact: Pierre Pollak, MD, PhD     0033476765791     pierre.pollak@ujf-grenoble.fr    
      Principal Investigator: Pierre Pollak, MD, PhD            
Hôpital La Timone     Recruiting
      Marseille, France, 13005
      Contact: Jean-Philippe Azulay, MD, PhD     0033491386579     jean-philippe.azulay@mail.ap-hm.fr    
      Principal Investigator: Jean-Philippe Azulay, MD, PhD            
Hôpital Charles Nicolle     Recruiting
      Rouen, France, 76000
      Contact: Didier Hannequin, MD, PhD     0033232888170     Didier.hannequin@chu-rouen.fr    
      Principal Investigator: Didier Hannequin, MD, PhD            
Hôpital Purpan     Recruiting
      Toulouse, France, 31000
      Contact: Patrick Calvas, MD, PhD     0033561779055     calvas.p@chu-toulouse.fr    
      Principal Investigator: Patrick Calvas, MD, PhD            

Sponsors and Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
Assistance Publique - Hôpitaux de Paris

Investigators
Principal Investigator:     Alexandra Dürr, MD, PhD     Assistance Publique - Hôpitaux de Paris    
Principal Investigator:     Broussolle Emmanuel, MD, PhD     Hôpitaux Civils de Lyon    
Principal Investigator:     Pierre Labauge, MD, PhD     Hôpitaux de Nîmes    
Principal Investigator:     Cyril Goizet, MD     Hôpitaux de Bordeaux    
Principal Investigator:     Patrick Calvas, MD, PhD     Hôpitaux de Toulouse    
Principal Investigator:     Jean-Philippe Azulay, MD, PhD     Assistance Publique - Hôpitaux de Marseille    
Principal Investigator:     Didier Hannequin, MD, PhD     Hôpitaux de Rouen    
Principal Investigator:     Pierre Pollak, MD, PhD     Hôpitaux de Grenoble    
  More Information

Related Info  This link exits the ClinicalTrials.gov site
 

Publications of Results:
Klebe S, Durr A, Rentschler A, Hahn-Barma V, Abele M, Bouslam N, Schols L, Jedynak P, Forlani S, Denis E, Dussert C, Agid Y, Bauer P, Globas C, Wullner U, Brice A, Riess O, Stevanin G. New mutations in protein kinase Cgamma associated with spinocerebellar ataxia type 14. Ann Neurol. 2005 Nov;58(5):720-9.
 
Stevanin G, Hahn V, Lohmann E, Bouslam N, Gouttard M, Soumphonphakdy C, Welter ML, Ollagnon-Roman E, Lemainque A, Ruberg M, Brice A, Durr A. Mutation in the catalytic domain of protein kinase C gamma and extension of the phenotype associated with spinocerebellar ataxia type 14. Arch Neurol. 2004 Aug;61(8):1242-8.
 
Stevanin G, Durr A, Dussert C, Penet C, Brice A. Mutations in the FGF14 gene are not a major cause of spinocerebellar ataxia in Caucasians. Neurology. 2004 Sep 14;63(5):936. No abstract available.
 
Waters MF, Minassian NA, Stevanin G, Figueroa KP, Bannister JP, Nolte D, Mock AF, Evidente VG, Fee DB, Muller U, Durr A, Brice A, Papazian DM, Pulst SM. Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat Genet. 2006 Feb 26; [Epub ahead of print]
 
Depienne C, Tallaksen C, Lephay JY, Bricka B, Poea-Guyon S, Fontaine B, Labauge P, Brice A, Durr A. Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from the one observed in familial cases. J Med Genet. 2005 Jul 31; [Epub ahead of print]
 
Depienne C, Fedirko E, Forlani S, Cazeneuve C, Ribai P, Feki I, Tallaksen C, Nguyen K, Stankoff B, Ruberg M, Stevanin G, Durr A, Brice A. Exon Deletions of SPG4 are a Frequent Cause of Hereditary Spastic Paraplegia. J Med Genet. 2006 Nov 10; [Epub ahead of print]
 
Depienne C, Fedirko E, Faucheux JM, Forlani S, Bricka B, Goizet C, Lesourd S, Stevanin G, Ruberg M, Durr A, Brice A. A de novo SPAST mutation leading to somatic mosaicism is associated with a later age at onset in HSP. Neurogenetics. 2007 Aug;8(3):231-233. Epub 2007 Jun 28.
 
Hanein S, Durr A, Ribai P, Forlani S, Leutenegger AL, Nelson I, Babron MC, Elleuch N, Depienne C, Charon C, Brice A, Stevanin G. A novel locus for autosomal dominant "uncomplicated" hereditary spastic paraplegia maps to chromosome 8p21.1-q13.3. Hum Genet. 2007 Jun 28; [Epub ahead of print]
 

Study ID Numbers:   AOM03059
First Received:   August 25, 2005
Last Updated:   October 16, 2007
ClinicalTrials.gov Identifier:   NCT00136630
Health Authority:   France: Ministry of Health

Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France:
dominant spinocerebellar degenerations  
new rate scales  
natural history  
molecular biology  
candidate genes  

Study placed in the following topic categories:
Spinal Cord Diseases
Paraplegia
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases
Dyskinesias
Paralysis
Cerebellar Ataxia
Signs and Symptoms
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn
Ataxia
Neurologic Manifestations
Cerebellar Diseases
Cerebellar ataxia
Spinocerebellar Degenerations
Spinocerebellar Ataxias

Additional relevant MeSH terms:
Nervous System Diseases

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers